Analysts have been eager to weigh in on the Healthcare sector with new ratings on Athersys (NASDAQ: ATHX), Intercept Pharma (NASDAQ: ICPT) and BioDelivery (NASDAQ: BDSI).
Athersys (NASDAQ: ATHX)
In a report released today, Jason Kolbert from Maxim Group reiterated a Buy rating on Athersys (NASDAQ: ATHX), with a price target of $9. The company’s shares opened today at $1.48.
Kolbert wrote:
“Summary Two important news items suggest to us that Athersys plans to develop Multistem is on the right track: 1. Biogen acquired acute ischemic stroke candidate Cirara glyburide (RP-1127) from Remedy Pharmaceuticals. Remedy is to receive $120 million up front and is eligible for milestones and royalties. See details below. 2. The WSJ published an article today: “New Research on Strokes Extends Window for Treatment”. Neurologists say pulling a clot from patients can carry powerful effects many hours later than previously thought. https://www.wsj.com/articles/new-research-on- strokes-extends-window-for-treatment-1494928980 Conclusion: Both data points suggest that reducing inflammation and managing the post stroke event can have a large impact on patient outcomes.”
According to TipRanks.com, Kolbert is ranked 0 out of 5 stars with an average return of -17.0% and a 30.4% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, ContraVir Pharmaceuticals Inc, and Brainstorm Cell Therapeutics.
Athersys has an analyst consensus of Moderate Buy, with a price target consensus of $9.
Intercept Pharma (NASDAQ: ICPT)
In a report released yesterday, Vernon Bernardino from FBR Capital reiterated a Hold rating on Intercept Pharma (NASDAQ: ICPT), with a price target of $138. The company’s shares opened today at $118.33.
Bernardino commented:
“We think the positive surprise of strong 1Q17 Ocaliva sales by Intercept Pharmaceuticals bodes well for continued sales growth in 2017, as the effects of rapid recommendation for Ocaliva’s use in PBC in the U.K. remain to be seen. We are impressed with the 47.8% QOQ growth in U.S. Ocaliva sales. Results from education and awareness programs in the U.S. are still nascent; thus, we expect moderate U.S. sales growth (10%–12%) to continue into YE17. Lastly, the REGENERATE Phase III trial appears to be on track; however, we look for top-line readouts from the CONTROL and AESOP trials that are expected midyear to be the next catalysts for the stock.”
According to TipRanks.com, Bernardino is ranked 0 out of 5 stars with an average return of -7.0% and a 30.1% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as ImmunoCellular Therapeutics, Actinium Pharmaceuticals, and Conatus Pharmaceuticals.
Currently, the analyst consensus on Intercept Pharma is Moderate Buy and the average price target is $188.14, representing a 59.0% upside.
In a report issued on May 4, Needham also reiterated a Hold rating on the stock.
BioDelivery (NASDAQ: BDSI)
FBR Capital analyst Edward White reiterated a Buy rating on BioDelivery (NASDAQ: BDSI) today and set a price target of $4. The company’s shares opened today at $2.10.
White observed:
“BioDelivery reported above-consensus 1Q17 results after the close on May 15. Management hosted a call to provide an update on 2017 progress. The company noted that net revenue for Belbuca hit an all-time high in March and reported $4.6 million in revenues for Belbuca in 1Q17. With regard to Bunavail, BioDelivery reiterated that it will limit its efforts to current prescribers and managed care contracts that will take effect this year. In addition, the company listed other options for longer-term growth of Belbuca in the U.S. and indicated opportunity to execute up to two commercial transactions for ex-U.S.”
According to TipRanks.com, White is ranked 0 out of 5 stars with an average return of -4.7% and a 42.0% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and RXi Pharmaceuticals Corp.
Currently, the analyst consensus on BioDelivery is Moderate Buy and the average price target is $3.83, representing an 82.4% upside.
In a report released today, Roth Capital also reiterated a Buy rating on the stock with a $4.50 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.